Antech Launches Breakthrough In-Hospital Innovation Nu.Q Canine Cancer Test
Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q Canine Cancer Test at this year’s annual VMX meeting.
Nu.Q will operate on Antech’s Heska Element i+ Immunodiagnostic Analyzer, an in-hospital platform which provides veterinarians with rapid, accurate, low cost and easy-to-use on-site testing in the veterinary clinic to support clinical decision-making and improve patient outcomes. Nu.Q (nucleosomes) assays are available from multiple sources, however the Nu.Q cartridge run on the Element i+ Immunodiagnostics Analyzer provides veterinarians with the first and only patient-side point of care test that provides accurate results in about 6 minutes.
Nu.Q is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers. Nu.Q testing run on the Element i+ analyzer is both cost-effective and simple, requiring only 50µL of EDTA plasma from a patient. Studies have shown >70 percent detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q .
The Nu.Q test can be carried out by veterinarians during annual check-ups, regular wellness exams, healthcare interventions and during cancer treatment cycles, to screen millions of dogs for some of the most common cancers, quickly providing accurate and critical information in minutes, patient-side.
Dr Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Petcare’s Science & Diagnostics division said: “This is an important milestone for veterinary diagnostics in helping veterinarians detect canine cancer, with expected greater accuracy patient-side and the convenience of avoiding transportation of samples. Knowing that almost half of dogs over the age of 10 will develop cancer[1], we have worked hard to bring the power of Nu.Q together with our high-tech in-hospital analyzers to support veterinary professionals and pets. We are proud of innovation and technology that supports our purpose: A BETTER WORLD FOR PETS.”
Antech, a trusted partner in delivering veterinary diagnostics for more than 35 years, offers a complete portfolio that spans reference laboratory services, in-hospital diagnostics, comprehensive imaging and technology solutions, advanced telemedicine services and innovative rapid diagnostics. To learn more about the in-hospital Nu.Q , visit booth 1522 at VMX 2024 or speak to your local Antech representative.
Nu.Q is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q Canine Cancer Test is supplied to Antech’s Heska affiliate under license by Belgian Volition SRL.